Related Experiment Video
Updated: Aug 15, 2026
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Postchemotherapy residual masses in advanced seminoma: current management and outcomes
Marcus L Quek1, Vannita Simma-Chiang, John P Stein
1Department of Urology, Loyola University Stritch School of Medicine, IL 60153, USA. mquek@lumc.edu
Abstract:
Although pure testicular seminoma is most often confined to the testis, it can present with advanced-stage bulky retroperitoneal metastases in nearly a quarter of cases. While highly treatable with cisplatin-based chemotherapy, up to 80% of patients with advanced disease are found to have a radiographically detectable residual mass after chemotherapy. The management of these postchemotherapy residual masses remains controversial. Surgical resection is technically challenging due to a desmoplastic reaction resulting from seminoma treatment and regression. In addition, these residual masses often demonstrate a protracted period of regression that can span several months to years. Surveillance protocols, therefore, may be appropriate for most patients. Several retrospective studies have supported surgical resection only for discrete, well-delineated masses over 3 cm in size. Despite the highly radiosensitive nature of seminoma, radiation therapy in this setting has not been shown to provide significant benefit, and may limit the tolerability of subsequent salvage chemotherapy. The incorporation of noninvasive imaging modalities, such as positron emission tomography, into the management algorithm may better delineate the presence of viable residual tumor and thus allow better risk stratification.
Insights
Management of residual masses after testicular seminoma chemotherapy is debated. Surveillance may be suitable for most patients, with surgery considered for discrete masses over 3 cm.
Area of Science:
- Oncology
- Urology
Background:
- Testicular seminoma can present with advanced retroperitoneal metastases.
- Post-chemotherapy residual masses are common in advanced seminoma, posing management challenges.
- Current management strategies for these residual masses remain controversial.
Purpose of the Study:
- To review the management of post-chemotherapy residual masses in advanced testicular seminoma.
- To discuss the controversies surrounding surgical resection, radiation therapy, and surveillance.
- To explore the role of advanced imaging in risk stratification.
Main Methods:
- Review of retrospective studies and clinical guidelines.
- Analysis of treatment outcomes for different management strategies.
- Discussion of the challenges associated with surgical resection and radiation therapy.
Main Results:
- Up to 80% of advanced seminoma patients have residual masses post-chemotherapy.
- Surgical resection is technically difficult due to desmoplastic reaction and protracted regression.
- Radiation therapy offers limited benefit and may impede salvage chemotherapy.
- Surveillance may be appropriate for most patients, with surgery considered for discrete masses >3 cm.
Conclusions:
- The management of post-chemotherapy residual masses in testicular seminoma requires careful consideration.
- Surveillance protocols are often appropriate, reserving surgery for select cases.
- Advanced imaging may improve risk stratification and guide treatment decisions.
